| Followers | 227 |
| Posts | 13601 |
| Boards Moderated | 0 |
| Alias Born | 03/15/2013 |
Tuesday, August 09, 2022 6:23:12 PM
Things like that happen with bio’s, it’’s still a promising company to invest in, theres other drug science capable of moving forward just like any other. those who followed us from the beginning of acad, at 2-5$ a share made a ton of wealth over the years whether they flipped in or out at variable times was their choice, its called trading, making wealth. To invest 25k at 3$ pps and to sell at 50 pps is a very large gain of wealth my friend. Those who didn’t sell well don’t blame acad for that. You think the BB’s invested not to sell? Ah, no they sure didn’t. We hold a chunk of acad yet but that is all free shares, no matter what price it goes to. As for other stocks you mentioned, it’s the same, wealth made an just sitting on free shares, who really cares what happens once your initial investment is paid for in gains. GL to you an never be greedy, take profits as u wish
Recent ACAD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 10:00:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:02:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:50:28 PM
- Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance • Business Wire • 05/06/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 10:00:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 10:00:18 PM
- Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career • Business Wire • 04/30/2026 08:05:00 PM
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 04/28/2026 08:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/28/2026 07:53:50 PM
- Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting • Business Wire • 04/17/2026 01:05:00 PM
- Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 • Business Wire • 04/15/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 11:57:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 11:55:40 PM
- Acadia launches powder version of Rett syndrome treatment in the U.S. • IH Market News • 04/07/2026 01:43:12 PM
- Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome • Business Wire • 04/07/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:01:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 10:00:14 PM
- Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum • Business Wire • 03/12/2026 08:05:00 PM
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors • Business Wire • 03/03/2026 09:05:00 PM
- Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome • Business Wire • 03/02/2026 09:05:00 PM
